FindTrial
Sign In

the discovery of cirRNA/lncRNA as biomarker of resistance to gefitinib in non-small cell lung cancer

the discovery of cirRNA/lncRNA as biomarker of resistance to gefitinib in non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014660
Enrollment
Unknown
Registered
2018-01-27
Start date
2018-02-26
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resistance to gefitinib in non-small cell lung cancer

Interventions

Control:none
Experiment:gefitinib

Sponsors

Institutes for Biological Sciences of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Sensitive group: clinically diagnosed as non-small cell lung cancer patients, no gefitinib was used, peripheral blood was taken, and the sensitive group was set. Drug resistance group: clinically diagnosed as non-small cell lung cancer patients, using gefitinib for treatment, after the disease progresses, take its peripheral blood, set to resistance group.

Exclusion criteria

Exclusion criteria: May interfere with non-coding RNA detection diseases: chronic viral infection, immune diseases, etc. Taking large doses before the trial may result in drugs that may affect the outcomeantibiotics, hormones, immunosuppressive agents, etc. During the treatment of gefitinib, the subjects used other chemotherapy drugs, such as paclitaxel and cisplatin.

Design outcomes

Primary

MeasureTime frame
the expression of non-coding RNAs;—

Countries

China

Contacts

Public ContactLanXiang Wu

Chongqing Medical University

420036136@qq.com+86 15023250939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026